The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
250 jobs Number of planned job losses
Announcement Date
28 October 2011
Employment effect (start)
1 December 2011
Foreseen end date
Description
Multinational pharmaceutical company Novo Nordisk, based in Bagsværd outside Copenhagen in Denmark, plans to cut 250 jobs in the European sales division.
Reasons for the restructuring are said to be the pressure on prices of insulin products. It is reported that health reforms and pressures from competitors have decreased growth in the insulin business in Europe to fewer than 3%, Novo informed on 28. October 2011.
Novo has 32000 employees in Europe of which ca. 43% work in Denmark.
Sources
28 October 2011: Borsen.dk
Citation
Eurofound (2011), Novo Nordisk, Internal restructuring in European Union, factsheet number 72794, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/72794.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
